? OVERALL The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an ?exceptional? overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.
The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research, education and community outreach and engagement as research conducted within the five OSUCCC Programs focuses on high priority cancers for the OSUCCC including lung, breast, colorectal, prostate, endometrial, cervical cancer, thyroid, and leukemia, as well as tobacco use, obesity and HPV vaccination. Screening and outreach activities are provided to the populations across the lifespan that we serve, especially those with higher burden of being diagnosd with cancer, such as racial/ethnic minorities and other underserved populations (e.g., rural, LGBTQ+, Appalachian) through targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, and addressing policy issues.
|Pettit, Cory; Webb, Amy; Walston, Steve et al. (2018) MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma. Oncotarget 9:28951-28964|
|Miller, Eric D; Fisher, James L; Haglund, Karl E et al. (2018) Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol 13:196|
|Fenn, J Daniel; Johnson, Christopher M; Peng, Juan et al. (2018) Kymograph analysis with high temporal resolution reveals new features of neurofilament transport kinetics. Cytoskeleton (Hoboken) 75:22-41|
|Colombo, Mara; Lòpez-Perolio, Irene; Meeks, Huong D et al. (2018) The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Hum Mutat 39:729-741|
|Hendricks, William P D; Zismann, Victoria; Sivaprakasam, Karthigayini et al. (2018) Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet 14:e1007589|
|Gardner, Heather L; Rippy, Sarah B; Bear, Misty D et al. (2018) Phase I/II evaluation of RV1001, a novel PI3K? inhibitor, in spontaneous canine lymphoma. PLoS One 13:e0195357|
|Barnhouse, Victoria R; Weist, Jessica L; Shukla, Vasudha C et al. (2018) Myoferlin regulates epithelial cancer cell plasticity and migration through autocrine TGF-?1 signaling. Oncotarget 9:19209-19222|
|Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4|
|Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618|
|Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29|
Showing the most recent 10 out of 2602 publications